On the Record · Charles River Laboratories International

Charles River Laboratories International acquisitions, on the record

The businesses Charles River Laboratories International bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.

Deals its annual reports describe

Business	Deal	When	Value
Noveprim Group Word for word“On November 30, 2023, we completed our acquisition of an additional 41% equity interest of Noveprim Group (“Noveprim”), a leading provider of non-human primates (“NHPs”) used for biomedical, pharmaceutical and toxicological research purposes, resulting in a 90% controlling interest.” 10-K for 2023	agreed acquisition	On November 30, 2023	—
SAMDI Tech, Inc. (SAMDI) Word for word“On January 30, 2023, we acquired SAMDI Tech, Inc., (SAMDI), a leading provider of high-quality, label-free high-throughput screening (HTS) solutions for drug discovery research.” 10-K for 2023	acquisition	On January 30, 2023	—
Explora BioLabs Holdings, Inc. (Explora BioLabs) Word for word“On April 5, 2022, we acquired Explora BioLabs Holdings, Inc. (Explora BioLabs), a provider of contract vivarium research services, providing biopharmaceutical clients with turnkey in vivo vivarium facilities, management and related services to efficiently conduct their early-stage research activities.” 10-K for 2023	acquisition	On April 5, 2022	—
Avian Vaccine Services (Avian) business Word for word“On December 20, 2022, we completed the sale of our Avian Vaccine Services (Avian) business to a private investor group for a preliminary purchase price of $167 million in cash, subject to certain customary closing adjustments, and future contingent payments up to an additional $30 million.” 10-K for 2023	divestiture	On December 20, 2022	a preliminary purchase price of $167 million in cash, subject to certain customary closing adjustments, and future contingent payments up to an additional $30 million
Avian Vaccine Services business Word for word“Most recently, we divested our Avian Vaccine Services business in 2022, and a Safety Assessment site in 2024, as we determined these businesses/sites were no longer a strategic fit.” 10-K for 2024	divestiture	in 2022	—
a Safety Assessment site Word for word“Most recently, we divested our Avian Vaccine Services business in 2022, and a Safety Assessment site in 2024, as we determined these businesses/sites were no longer a strategic fit.” 10-K for 2024	divestiture	in 2024	—
Explora BioLabs Word for word“Acquisitions, such as our acquisitions of Explora BioLabs in fiscal 2022, SAMDI in 2023, and Noveprim in 2023, have been (and we expect will be in the future) an integral part of our growth strategy, both to expand our portfolio and broaden our geographic footprint.” 10-K for 2024	acquisition	in fiscal 2022	—
Noveprim Group (Noveprim) Word for word“On November 30, 2023, we completed our acquisition of an additional 41% equity interest of Noveprim Group (Noveprim), a leading supplier of non-human primates (NHPs) located in Mauritius, resulting in a 90% controlling interest.” 10-K for 2024	acquisition	On November 30, 2023	—
K.F. (Cambodia) Ltd Word for word“On January 14, 2026, we completed the acquisition of certain assets of K.F. (Cambodia) Ltd (KF)., a leading supplier of non-human primates (NHPs) located in Cambodia. ” 10-K for 2025	acquisition	On January 14, 2026	—
PathoQuest SAS Word for word“On January 9, 2026, we announced we have exercised our option to acquire the remaining 79% equity interest in PathoQuest SAS (PathoQuest) for €51.6 million (or approximately $60 million based on current exchange rates), subject to customary closing adjustments.” 10-K for 2025	agreed acquisition	On January 9, 2026	€51.6 million
SAMDI Tech, Inc. Word for word“The purchase price of SAMDI was $62.8 million, net of $0.4 million in cash, inclusive of a 20% strategic equity interest previously owned by us of $12.6 million.” 10-K for 2025	acquisition	—	$62.8 million

As filedReported in the company's financial data (XBRL), each linked to its filing
Fiscal year ended	Cash paid for acquisitions (net of cash acquired)	Goodwill from acquisitions
2016-12-31	$648.5 million	—
2017-12-30	$25 million	—
2018-12-29	$824.9 million	—
2019-12-28	$515.7 million	—
2020-12-26	$418.6 million	—
2021-12-25	$1.29 billion	—
2022-12-31	$283.4 million	—
2023-12-30	$194.8 million	$209.5 million
2024-12-28	$5.5 million	$17.7 million
2025-12-27	$0	—

Deal filings since 2016

2025-05-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2021-03-29 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2021-03-23 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2021-02-17 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-10-23 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-05-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-05-01 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2019-02-15 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2018-06-14 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2018-04-03 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2018-04-03 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2018-02-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-06-15 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2016-04-05 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2016-01-08 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement

Read from Charles River Laboratories International’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-18. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.